- Home
- » Tags
- » Etelcalcetide
Top View
- Parsabiv H-3995
- One-Year Safety and Efficacy of Intravenous Etelcalcetide in Patients on Hemodialysis with Secondary Hyperparathyroidism
- Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide
- Product List
- Pharmacoeconomic Evaluation of Antibiotic Therapy of Community
- New Drugs 2018, Part 3
- Parsabiv™ (Etelcalcetide)
- Etelcalcetide, a Novel Synthetic, D-Amino Acid Peptide
- Advancements and Technologies Driving Peptide Drug Design and Development
- Calcimimetic (Cinacalcet, Etelcalcetide) Criteria for Use January 2018
- CP.PHAR.379 Etelcalcetide (Parsabiv)
- Effect of Etelcalcetide Vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism a Randomized Clinical Trial
- Parsabiv Generic Name2,4: Etelcalcetide Manufacturer4
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- Etelcalcetide for Treating Secondary Hyperparathyroidism 1 Recommendations
- Seres's Pioneering Microbiome Drug Fails Mid-Stage Trial
- Report on the Deliberation Results November 14, 2016
- ― D06 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
- Parsabiv™ (Etelcalcetide) Injection
- Regulatory Issues Concerning the Preclinical Testing of Synthetic Peptides
- Allwell from Buckeye Health Plan Prior Authorization Updates
- Paragraph IV Patent Certifications (PPIV)
- Flourous Metabolically Stable Peptide Analogs
- Ag-Atc-Beschluss-20171124.Pdf
- Effect of Switching from Cinacalcet To
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Old and New Calcimimetics for Treatment Of
- Download Product Insert (PDF)
- Nonclinical Pharmacokinetics, Disposition, and Drug-Drug
- Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing
- Launch of Parsabiv® Intravenous Injection Syringe for Dialysis, a Calcimimetic Agent in Japan
- Only One Calcimimetic Lowers and Maintains Key Shpt Lab Values with IV Administration You Control1
- Report on the Deliberation Results March 8, 2018 Pharmaceutical
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- 208325Orig1s000